Announcement on Related Transactions of Peak Pharmaceutical's Capital Increase
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 公告编号:临2019-013
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
关于尖峰药业增资的关联交易公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
l 拟增资控股子公司名称:浙江尖峰药业有限公司(以下简称:尖峰药业)
l 拟增资金额:10000万元,其中:本公司出资9916万元。
l 特别风险提示:尖峰药业是本公司与金华市通济国有资产投资有限公司(以下简称“通济国投”)共同出资组建,本公司占注册资本的99.16%、通济国投占0.84%。通济国投是本公司第一大股东,持有本公司16.15%股权,为本公司关联法人,本次共同对尖峰药业增资属于关联交易事项。
一、关联交易概述
(一)本次增资基本情况
浙江尖峰药业有限公司是本公司的控股子公司,近年来尖峰药业的投资较多,资金需求较大,导致尖峰药业的负债率偏高,为了优化尖峰药业财务结构、增加实力,本公司及通济国投拟以货币方式共同对尖峰药业进行增资,本次增资总额为人民币10,000万元,各股东按持股比例增资。
(二)关联交易履行的审议程序
本次关联交易,本公司出资金额为9916万元,未超过公司2018年度经审计净资产的5%,且不构成《上市公司重大资产重组管理办法》规定的重大资产重组。根据上海证券交易《股票上市规则》及公司《章程》的规定,需提交董事会审议,但不需要提交股东大会审议。
2019年4月26日,公司召开了第十届董事会第10次会议,公司现有九名董事,其中八名董事亲自参加了会议,杜自弘董事委托蒋晓萌董事代为出席会议并表决,根据《上海证券交易所股票上市规则》的规定,本公司董事会就上述议案进行表决时,公司关联董事蒋晓萌、刘波先生需回避该议案的表决。经审议与表决,董事会以7票同意、0票反对、0票弃权审议通过了《关于尖峰药业增资的关联交易议案》。
公司独立董事对该事项进行了事前审议,同意将该议案提交给公司第十届董事会第10次会议审议,并对董事会通过该议案发表了同意的独立意见,认为:该关联交易事项的相关资料准备齐全,交易双方以相同价格、按原比例增资,交易价格公允。该决议的形成符合《公司法》、公司《章程》等有关规定,未发现有损害公司及中小股东权益的情形。同意对尖峰药业增资的关联交易。
二、关联方介绍
(一)关联方的基本情况
1、名称:金华市通济国有资产投资有限公司
2、企业性质:有限责任公司(国有独资)
3、注册地:浙江省金华市婺城区八一南街387号信华大楼401-406室
4、法定代表人:刘波
5、注册资本:人民币9500万元
6、主营业务:一般经营项目:授权的国有资产投资、经营。
7、关联人最近一年的主要财务指标
截止2018年12月31日,通济国投的资产总额35558.1万元,净资产35444.48万元,净利润为1692.04万元。(未经具有证券从业资格的会计师事务所审计)
(二)关联关系
通济国投是本公司第一大股东,持有本公司16.15%股权,为本公司关联法人,且公司董事长蒋晓萌先生、董事刘波先生兼任通济国投的董事,按照《上海证券交易所股票上市规则》有关规定,本次共同对尖峰药业增资属于关联交易事项。
三、尖峰药业的基本情况
1、交易标的基本情况
(1)名称:浙江尖峰药业有限公司
(2)企业性质:有限责任公司
(3)注册地:浙江金华市婺城区白汤下线高畈段58号X02幢办公质检楼二楼
(4)法定代表人:蒋晓萌
(5)注册资本:人民币19853万元
(6)主营业务:药品研发与生产(凭有效许可证件经营);进口生产、科研所需的原辅料;进口机械设备、仪器仪表及零配件。(依法须经批准的项目,经相关部门批准后方可开展经营活动)
尖峰药业由本公司与通济国投共同出资组建,本公司占注册资本的99.16%、通济国投占0.84%。
2、尖峰药业的主要合并财务数据(单位:万元)
|
科目 |
2018年12月31日 |
|
资产总额 |
144410.77 |
|
负债总额 |
105736.43 |
|
归属于母公司所有者股东权益 |
38674.34 |
|
资产负债率 |
73.22% |
|
|
2018年度 |
|
营业收入 |
148762.44 |
|
归属于母公司所有者净利润 |
3696.70 |
以上财务指标经据有证券从业资格的天健会计师事务所审计。
四、关联交易的主要内容
(一)关联交易价格确定的原则和方法
本次增资,尖峰药业原股东双方按原比例共同增资,以按每元注册资本1元的价格进行增资。
(二)本次增资总额为人民币10,000万元,本公司持有尖峰药业99.16%的股权,按持股比例享有9916万元的增资权;通济国投持有尖峰药业0.84%的股权,按持股比例享有84万元的增资权。
本公司以现金向尖峰药业进行增资,出资金额9916万元;通济国投以现金向尖峰药业进行增资,出资金84万元。
增资完成后,尖峰药业的注册资本增加到29853万元,各股东的持股比例保持不变。
(三)双方的增资款,在2019年9月30日前汇至尖峰药业账户。
五、该关联交易的目的以及对上市公司的影响
由尖峰药业经营的医药业务是公司两大主营业务之一,对尖峰药业的增资有助于改善其资产结构,增强公司实力和竞争力。尖峰药业的发展壮大,将有助于公司医药产业的健康持续发展。
特此公告。
l 报备文件
(一)公司第十届董事会第10次会议决议
(二)第九届监事会第6次会议决议;
(三)独立董事的独立意见
(四)独立董事关于公司关联交易的事前认可事项
浙江尖峰集团股份有限公司
董事会
More information
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-31
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-30
Peak Pharmaceutical Becomes National Intellectual Property Demonstration Enterprise
Just one year after it was identified as a national intellectual property advantage enterprise in 2016, "Zhejiang Jianfeng Pharmaceutical Co., Ltd." appeared in the list of national intellectual property demonstration enterprises in 2017 recently announced by the State Intellectual Property Office. As a result, Jianfeng Pharmaceutical has become the first and only national intellectual property demonstration enterprise in Jinhua City. On December 12, the State Intellectual Property Office issued a notice to announce the list of national intellectual property demonstration enterprises and advantageous enterprises in 2017. After the enterprise declaration, the recommendation of the provincial and municipal bureaus, the review of the national bureau, and the public announcement, 182 national intellectual property demonstration enterprises and 816 national intellectual property advantage enterprises have been identified. Including Jianfeng Pharmaceutical, Zhejiang Province has been identified as only 15 national intellectual property demonstration enterprises. With the continuous development of enterprises in recent years, Jianfeng Pharmaceutical has set up a special working organization to cultivate and improve the intellectual property ability from the aspects of strategic management, creation, operation and protection of intellectual property rights. It has successively compiled and implemented 27 procedural documents and 36 forms such as "Intellectual Property Management Manual", "Intellectual Property Reward and Punishment System" and "Trade Secret Management System, and timely according to the policy, the current situation of the enterprise to revise, in order to ensure the compliance and effectiveness of the operation of the system. In 2012 and 2013, Jianfeng Pharmaceutical was successively rated as a patent demonstration enterprise in Jinhua City and Zhejiang Province; in 2013, it won the third prize of Jinhua Patent Implementation Award; in 2016, it passed the certification of intellectual property management system and was identified as a national intellectual property advantage enterprise. Currently, Peak Pharmaceuticals has
2020
07-31
Jianfeng Pharmaceutical Approved to Set up Provincial Research Institute
A few days ago, the relevant departments of Zhejiang Province approved the establishment of the provincial research institute of the peak pharmaceutical company. This is another honor won by Jianfeng Pharmaceutical in the field of independent research and development and scientific and technological innovation after the national postdoctoral research workstation and Zhejiang academician expert workstation. The provincial enterprise research institute is a high-level R & D institution led by the Provincial Department of Science and Technology, jointly recognized by the Provincial Economic and Information Commission and the Provincial Development and Reform Commission. As an important part of the national technological innovation system, the Enterprise Research Institute is the core force of the innovation-driven development of Jianfeng Pharmaceutical, which reflects the ability of Jianfeng Pharmaceutical to set up higher-level and higher-level R & D institutions on its own. the ability to gather and integrate innovation elements, organize scientific and technological innovation, support the sustainable development of enterprises, and lead the technological progress of the industry. As a pharmaceutical enterprise, scientific and technological innovation is the eternal theme of enterprise development, and talent is the key to scientific and technological innovation. Over the years, Jianfeng Pharmaceutical has not only focused on cultivating its own scientific research talents, but also established close cooperative relations with well-known universities and scientific research institutions such as China Pharmaceutical University, Shenyang Pharmaceutical University, Sichuan Antibiotic Industry Research Institute, and also focused on introducing top think tanks. In 2011, Professor Liu Jiajian and his team from Sichuan Institute of Antibiotic Industry were introduced, focusing on the technical research of key intermediates of methoxy cephalosporin. In 2013, Professor Shan Weiguang and his scientific research team from Zhejiang University of Technology were introduced to carry out research on preparation technology. In 2015, Professor Wang Guangji, academician of the Chinese Academy of Engineering, was hired as the chief scientist to organize the research on the anti-drug resistance mechanism of national class I new drugs by intracellular pharmacokinetics. In 2017 with Shanghai antibody
2020
07-31
On November 16, the company held the first extraordinary general meeting of shareholders in 2017, which deliberated and passed the proposal on the expiration of the term of the board of directors and the proposal on the expiration of the term of the board of supervisors, and elected a new board of directors and the board of supervisors. The meeting used a combination of on-site registered voting and online voting to vote on director candidates one by one, and elected Jiang Xiaomeng, Du Zihong, Yu Jianhong, Huang Sujian, Liu Bo, Zhang Guoping, Huang Conyun, Sun Hongbin, and Shi Ximin as the company's tenth board of directors. Directors, of which Huang Conyun, Sun Hongbin, and Shi Ximin are independent directors. The meeting used a combination of on-site registered voting and online voting to vote on supervisor candidates one by one, and elected Chen Tianci, Lu Ruimei, and Shi Fu as supervisors of the company's ninth board of supervisors. Prior to this, the company's trade union held an enlarged meeting of the trade union committee to elect Qin Xuping and Jin Huazhong as employee representative supervisors of the ninth board of supervisors. On the same day, the company's tenth board of directors held its first meeting and elected Jiang Xiaomeng as the chairman of the tenth board of directors. Jiang Xiaomeng, Du Zihong, Huang Sujian, Sun Hongbin and Shi Ximin were elected as members of the Strategy Committee of the 10th Board of Directors, and Jiang Xiaomeng was the chairman of the Strategy Committee. Shi Ximin, Huang Conyun and Jiang Xiaomeng were elected as members of the audit committee of the 10th board of directors, and Shi Ximin was the chairman. Sun Hongbin, Huang Conyun and Jiang Xiaomeng were elected as members of the nomination committee of the 10th board of directors, and Sun Hongbin was the chairman. Huang Cong Yun, Shi Ximin and Du Zihong were elected as members of the remuneration and assessment committee of the 10th board of directors, and Huang Cong Yun was the chairman. The board of directors appointed Yu Jianhong as the general manager of the company and appointed Huang Jinlong.
2020
07-31
Peak natural products pollution control results by the industry attention
As a leader in China's plant extracts industry, Tianjin Jianfeng Natural Products Company has achieved fruitful results in technological innovation. On October 26 and 27, at the 2017 Forum on improving the international competitiveness of China's plant extract industry held in Handan City, Hebei Province, Liu Dan, general manager of the company, delivered a speech entitled "prevention and control of water pollution in the field of plant extraction", introducing the successful experience of sewage treatment in the past five years, which was widely concerned by the participants. In recent years, environmental protection and ecology have become hot words for the development of enterprises and society. Due to the particularity of the plant extraction industry, pollution control in this industry has different characteristics and requirements from ordinary production enterprises. For example, sewage presents higher chroma, extremely low PH value, more suspended solids, high salinity, high concentration of COD, and different sewage water quality of different products. As the earliest enterprise producing opc grape seed extract in China, Natural Products Company has always attached great importance to the pollution control of plant extraction. For example, in the sewage treatment upgrading project implemented in 2016, ozone oxidation and biochemical methods were adopted to remove the remaining organic pollutants, increasing the sewage treatment capacity from 200 cubic meters per day to 500 cubic meters. The latest anaerobic sewage treatment technology is adopted, the COD emission value of the outlet is reduced to 60 mg per liter, which is far lower than the national first-class emission standard of 100 mg per liter. The new system adopts advanced oxidation reaction tower, ozonation method, field energy reactor and sludge adsorption reflux technology, which can quickly and efficiently treat organic pollutants with strong chemical stability without adding any chemicals.
2020
07-31